Cited by 2,027Global Cancer Incidence and ScreeningColorectal Cancer Screening and DetectionEsophageal Cancer Research and Treatment

Global Burden of 5 Major Types of Gastrointestinal Cancer

Open access
Arnold, Melina, Abnet, Christian C., Neale, Rachel E., Vignat, Jerome, Giovannucci, Edward L., McGlynn, Katherine A., Bray, Freddie·2020·Gastroenterology

Abstract

Background & aims There were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence and 35% of all cancer-related deaths. We investigated the global burden from the 5 major GI cancers, as well as geographic and temporal trends in cancer-specific incidence and mortality. Methods Data on primary cancers of the esophagus, stomach, colorectum, liver, and pancreas were extracted from the GLOBOCAN database for the year 2018, as well as from the Cancer Incidence in 5 Continents series, and the World Health Organization mortality database from 1960 onward. Age-standardized incidence and mortality rates were calculated by sex, country, and level of human development. Results We observed geographic and temporal variations in incidence and mortality for all 5 types of GI cancers. Esophageal, gastric, and liver cancers were more common in Asia than in other parts of the world, and the burden from colorectal and pancreatic cancers was highest in Europe and North America. There was a uniform decrease in gastric cancer incidence, but an increasing incidence of colorectal cancer in formerly low-incidence regions during the studied time period. We found slight increases in incidence of liver and pancreatic cancer in some high-income regions. Conclusions Although the incidence of some GI cancer types has decreased, this group of malignancies continues to pose major challenges to public health. Primary and secondary prevention measures are important for controlling these malignancies-most importantly reducing consumption of tobacco and alcohol, obesity control, immunizing populations against hepatitis B virus infection, and screening for colorectal cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2020.02.068

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Colorectal cancer incidence rates have been steadily rising in countries undergoing major transition, including countries in Eastern Europe, South-Eastern and South-Central Asia, and South America.

    “colorectal cancer incidence rates have been steadily rising in countries undergoing major transition, 61,62 including countries in Eastern Europe, South-Eastern and South-Central Asia, and South America.63,64”

    From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [63]

    The Results & Discussion section on colorectal cancer (page not available) says incidence is rising rapidly in many less-developed countries, particularly in Eastern Europe, Asia, and South America. It does not specifically identify South-Eastern or South-Central Asia as regions with rising rates; its mention of South-Central Asia concerns its low incidence rate, not a trend. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • With declines in the population seroprevalence of HBV and HCV, as well as a reduction in aflatoxin exposure, liver cancer rates have been declining steadily in many high-risk countries in East and South-Eastern Asia since the late 1970s and in Japan and China since the 1990s.

    “With declines in the population seroprevalence of HBV and HCV, as well as a reduction in aflatoxin exposure, liver cancer rates have been declining steadily in many high-risk countries in East and South-Eastern Asia since the late 1970s and in Japan and China since the 1990s.63,125,126”

    From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [63]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • The declines in colorectal cancer incidence in many high-incidence countries over the last decades have been considered the result of population-level shifts toward a healthier lifestyle and the introduction of screening.

    “The declines in colorectal cancer incidence in many high-incidence countries over the last decades have been considered the result of population-level shifts toward a healthier lifestyle (e.g., increased access to sources of fiber, such as fruits and vegetables) and the introduction of screening, 63,70”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [17]Day NE. A New Measure of Age Standardized Incidence, the Cumulative Rate. In: Waterhouse J, Muir CS, Correa P, Powell C, eds. Cancer incidence in Five Continents, Vol III (IARC Scientific Publications No 15). Lyon: International Agency for Research on Cancer; 1976: 443– 52.
  2. [21]Semnani SH, Besharat S, Abdolahi N, Esophageal cancer in northeastern Iran. Indian J Gastroenterol 2005; 24(5): 224. 16361775
  3. [34]De Martel C, Georges D, Bray F, Ferlay J, Clifford G. The global burden of cancer attributable to infections in 2018. Lancet Glob Health 2019; in press. 31862245

Cited by

Sorted by citations

Authors
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F.
Affiliations
  • Centre international de recherche sur le cancer (FR)
  • National Cancer Institute (US)
  • Harvard University (US)
Corresponding author
Arnold, Melina
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2020-07
Volume
159
Issue
1
Pages
335-349.e15
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3014713533
Cited by
2,027
References
71
Citations by year
2026: 246 · 2025: 450 · 2024: 447 · 2023: 378 · 2022: 296 · 2021: 165 · 2020: 43 · 2012: 1
FWCI
79.92
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • World Health Organization
  • National Institutes of Health
  • National Cancer Institute (Z01CP000185)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
Keywords
gastrointestinal cancer, global cancer burden, cancer incidence, cancer mortality, esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, regional variation, temporal trends, human development, cancer prevention, hepatitis B vaccination, colorectal cancer screening, alcohol and tobacco use, obesity
MeSH terms
Global Burden of Disease, Aged, Americas, Asia, Europe, Female, Gastrointestinal Neoplasms, Geography, Health Services Needs and Demand, Humans, Liver Neoplasms, Male, Mass Screening, Mortality, Pancreatic Neoplasms, Risk Factors, Sex Factors, Global Health, Incidence, Databases, Factual, Australasia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review